CVAC Stock Overview
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
Price History & Performance
|Historical stock prices|
|Current Share Price||US$13.18|
|52 Week High||US$75.68|
|52 Week Low||US$12.39|
|1 Month Change||0.15%|
|3 Month Change||-32.10%|
|1 Year Change||-80.04%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-76.42%|
Recent News & Updates
CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
German biotech CureVac N.V. (NASDAQ:CVAC) announced on Tuesday that the company filed a lawsuit in Germany over the infringement of certain intellectual property rights related to the COVID-19 vaccine developed by its local rival BioNTech (BNTX) and U.S. pharma giant Pfizer (PFE). The case was filed in the German Regional Court in Düsseldorf against BioNTech (BNTX) and two of its subsidiaries, CureVac (CVAC) said, noting it would fair compensation for the alleged violations. While CureVac (CVAC) has added ~1%, both BioNTech (BNTX) and Pfizer (PFE) have lost ~1% in the pre-market so far. However, the company said that it would not seek an injunction or resort to a legal action that could disrupt the production and sales of the blockbuster vaccine. The IP rights titled EP 1 857 122 B1, DE 20 2015 009 961 U1 relate to the development of mRNA, the compound behind the Pfizer (PFE)/ BioNTech (BNTX) COVID-19 vaccine.
|CVAC||US Biotechs||US Market|
Return vs Industry: CVAC underperformed the US Biotechs industry which returned -22.2% over the past year.
Return vs Market: CVAC underperformed the US Market which returned -8.9% over the past year.
|CVAC Average Weekly Movement||9.0%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: CVAC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CVAC's weekly volatility (9%) has been stable over the past year.
About the Company
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck.
CureVac Fundamentals Summary
|CVAC fundamental statistics|
Is CVAC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CVAC income statement (TTM)|
|Cost of Revenue||€255.75m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.67|
|Net Profit Margin||-266.86%|
How did CVAC perform over the long term?See historical performance and comparison
Is CVAC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CVAC?
Other financial metrics that can be useful for relative valuation.
|What is CVAC's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CVAC's PS Ratio compare to its peers?
|CVAC PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ACAD ACADIA Pharmaceuticals
IMCR Immunocore Holdings
BCRX BioCryst Pharmaceuticals
MYGN Myriad Genetics
Price-To-Sales vs Peers: CVAC is expensive based on its Price-To-Sales Ratio (20.7x) compared to the peer average (12.6x).
Price to Earnings Ratio vs Industry
How does CVAC's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: CVAC is expensive based on its Price-To-Sales Ratio (20.7x) compared to the US Biotechs industry average (16.9x)
Price to Sales Ratio vs Fair Ratio
What is CVAC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||20.7x|
|Fair PS Ratio||1.6x|
Price-To-Sales vs Fair Ratio: CVAC is expensive based on its Price-To-Sales Ratio (20.7x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).
Share Price vs Fair Value
What is the Fair Price of CVAC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CVAC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CVAC's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is CureVac forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CVAC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: CVAC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CVAC is expected to become profitable in the next 3 years.
Revenue vs Market: CVAC's revenue (29% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: CVAC's revenue (29% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CVAC is forecast to be unprofitable in 3 years.
Discover growth companies
How has CureVac performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CVAC is currently unprofitable.
Growing Profit Margin: CVAC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CVAC is unprofitable, and losses have increased over the past 5 years at a rate of 53.3% per year.
Accelerating Growth: Unable to compare CVAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CVAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: CVAC has a negative Return on Equity (-46.4%), as it is currently unprofitable.
Discover strong past performing companies
How is CureVac's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CVAC's short term assets (€789.3M) exceed its short term liabilities (€237.8M).
Long Term Liabilities: CVAC's short term assets (€789.3M) exceed its long term liabilities (€114.0M).
Debt to Equity History and Analysis
Debt Level: CVAC is debt free.
Reducing Debt: CVAC had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CVAC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CVAC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is CureVac current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CVAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CVAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CVAC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CVAC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CVAC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Franz-Werner Haas (52 yo)
Dr. Franz-Werner Haas, LLD, LLM, PhD, has been Chief Executive Officer of CureVac AG since June 2020 and has been its Chief Operating Officer since 2018 and also serves as its Member of Management Board. H...
CEO Compensation Analysis
Compensation vs Market: Franz-Werner's total compensation ($USD545.44K) is below average for companies of similar size in the US market ($USD6.57M).
Compensation vs Earnings: Franz-Werner's compensation has been consistent with company performance over the past year.
Experienced Management: CVAC's management team is considered experienced (2.1 years average tenure).
Experienced Board: CVAC's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
CureVac N.V.'s employee growth, exchange listings and data sources
- Name: CureVac N.V.
- Ticker: CVAC
- Exchange: NasdaqGM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$2.465b
- Shares outstanding: 187.03m
- Website: https://www.curevac.com
Number of Employees
- CureVac N.V.
- Friedrich-Miescher-Strasse 15
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/17 00:00|
|End of Day Share Price||2022/08/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.